160 related articles for article (PubMed ID: 20187963)
21. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
[TBL] [Abstract][Full Text] [Related]
22. Application of the GA/KNN method to SELDI proteomics data.
Li L; Umbach DM; Terry P; Taylor JA
Bioinformatics; 2004 Jul; 20(10):1638-40. PubMed ID: 14962943
[TBL] [Abstract][Full Text] [Related]
23. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Engwegen JY; Gast MC; Schellens JH; Beijnen JH
Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
[TBL] [Abstract][Full Text] [Related]
24. SELDI-TOF serum proteomics and breast cancer: which perspective?
Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
[TBL] [Abstract][Full Text] [Related]
25. Proteiomic patterns for endometrial cancer using SELDI-TOF-MS.
Zhu LR; Zhang WY; Yu L; Zheng YH; Hu J; Liao QP
J Zhejiang Univ Sci B; 2008 Apr; 9(4):286-90. PubMed ID: 18381802
[TBL] [Abstract][Full Text] [Related]
26. SELDI-TOF MS Analysis of Hepatocellular Carcinoma in an Australian Cohort.
Schlichtemeier SM; Nahm CB; Xue A; Gill AJ; Smith RC; Hugh TJ
J Surg Res; 2019 Jun; 238():127-136. PubMed ID: 30771682
[TBL] [Abstract][Full Text] [Related]
27. The value of surface enhanced laser desorption/ionization-time of flight mass spectrometry at the diagnosis of non-small cell lung cancer: a systematic review.
Jiang F; Zhou XY; Huang J
Technol Cancer Res Treat; 2014 Apr; 13(2):109-17. PubMed ID: 23862745
[TBL] [Abstract][Full Text] [Related]
28. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
29. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
Bouamrani A; Ternier J; Ratel D; Benabid AL; Issartel JP; Brambilla E; Berger F
Clin Chem; 2006 Nov; 52(11):2103-6. PubMed ID: 16990423
[TBL] [Abstract][Full Text] [Related]
30. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
Hong H; Dragan Y; Epstein J; Teitel C; Chen B; Xie Q; Fang H; Shi L; Perkins R; Tong W
BMC Bioinformatics; 2005 Jul; 6 Suppl 2(Suppl 2):S5. PubMed ID: 16026602
[TBL] [Abstract][Full Text] [Related]
31. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Gonçalves A; Bertucci F; Birnbaum D; Borg JP
Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Semmes OJ; Feng Z; Adam BL; Banez LL; Bigbee WL; Campos D; Cazares LH; Chan DW; Grizzle WE; Izbicka E; Kagan J; Malik G; McLerran D; Moul JW; Partin A; Prasanna P; Rosenzweig J; Sokoll LJ; Srivastava S; Srivastava S; Thompson I; Welsh MJ; White N; Winget M; Yasui Y; Zhang Z; Zhu L
Clin Chem; 2005 Jan; 51(1):102-12. PubMed ID: 15613711
[TBL] [Abstract][Full Text] [Related]
33. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
Zeidan BA; Townsend PA
Breast Cancer Res; 2008; 10(3):107. PubMed ID: 18644101
[TBL] [Abstract][Full Text] [Related]
34. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
35. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data.
Wu B; Abbott T; Fishman D; McMurray W; Mor G; Stone K; Ward D; Williams K; Zhao H
Bioinformatics; 2003 Sep; 19(13):1636-43. PubMed ID: 12967959
[TBL] [Abstract][Full Text] [Related]
36. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools.
Bhattacharyya S; Epstein J; Suva LJ
Dis Markers; 2006; 22(4):245-55. PubMed ID: 17124346
[TBL] [Abstract][Full Text] [Related]
38. Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum.
Lilien RH; Farid H; Donald BR
J Comput Biol; 2003; 10(6):925-46. PubMed ID: 14980018
[TBL] [Abstract][Full Text] [Related]
39. Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry.
Liu Q; Chen X; Hu C; Zhang R; Yue J; Wu G; Li X; Wu Y; Wen F
Lung; 2010; 188(1):15-23. PubMed ID: 20012079
[TBL] [Abstract][Full Text] [Related]
40. Application of the random forest classification algorithm to a SELDI-TOF proteomics study in the setting of a cancer prevention trial.
Izmirlian G
Ann N Y Acad Sci; 2004 May; 1020():154-74. PubMed ID: 15208191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
